Li Wenjun, Terada Yuriko, Bai Yun Zhu, Yokoyama Yuhei, Shepherd Hailey M, Amrute Junedh M, Bery Amit I, Liu Zhiyi, Gauthier Jason M, Terekhova Marina, Bharat Ankit, Ritter Jon H, Puri Varun, Hachem Ramsey R, Turnquist Hēth R, Sage Peter T, Alessandrini Alessandro, Artyomov Maxim N, Lavine Kory J, Nava Ruben G, Krupnick Alexander S, Gelman Andrew E, Kreisel Daniel
Department of Surgery.
Department of Medicine, and.
J Clin Invest. 2025 Mar 18;135(10). doi: 10.1172/JCI178975. eCollection 2025 May 15.
Mechanisms that mediate allograft tolerance differ between organs. We have previously shown that Foxp3+ T cell-enriched bronchus-associated lymphoid tissue (BALT) is induced in tolerant murine lung allografts and that these Foxp3+ cells suppress alloimmune responses locally and systemically. Here, we demonstrated that Foxp3+ cells that reside in tolerant lung allografts differed phenotypically and transcriptionally from those in the periphery and were clonally expanded. Using a mouse lung retransplant model, we showed that recipient Foxp3+ cells were continuously recruited to the BALT within tolerant allografts. We identified distinguishing features of graft-resident and newly recruited Foxp3+ cells and showed that graft-infiltrating Foxp3+ cells acquired transcriptional profiles resembling those of graft-resident Foxp3+ cells over time. Allografts underwent combined antibody-mediated rejection and acute cellular rejection when recruitment of recipient Foxp3+ cells was prevented. Finally, we showed that local administration of IL-33 could expand and activate allograft-resident Foxp3+ cells, providing a platform for the design of tolerogenic therapies for lung transplant recipients. Our findings establish graft-resident Foxp3+ cells as critical orchestrators of lung transplant tolerance and highlight the need to develop lung-specific immunosuppression.
介导同种异体移植耐受的机制在不同器官之间存在差异。我们之前已经表明,在耐受的小鼠肺同种异体移植中会诱导出富含Foxp3+ T细胞的支气管相关淋巴组织(BALT),并且这些Foxp3+细胞在局部和全身抑制同种免疫反应。在这里,我们证明了存在于耐受肺同种异体移植中的Foxp3+细胞在表型和转录水平上与外周的细胞不同,并且是克隆性扩增的。使用小鼠肺再移植模型,我们表明受体Foxp3+细胞持续被招募到耐受同种异体移植中的BALT。我们确定了移植组织驻留和新招募的Foxp3+细胞的区别特征,并表明随着时间的推移,移植组织浸润的Foxp3+细胞获得了类似于移植组织驻留Foxp3+细胞的转录谱。当受体Foxp3+细胞的招募被阻止时,同种异体移植会发生抗体介导的排斥反应和急性细胞排斥反应。最后,我们表明局部给予IL-33可以扩增并激活移植组织驻留的Foxp3+细胞,为设计肺移植受者的耐受性疗法提供了一个平台。我们的研究结果确立了移植组织驻留的Foxp3+细胞是肺移植耐受的关键协调者,并强调了开发肺特异性免疫抑制的必要性。